Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 3, 2012, Pages 293-301

  Wasan, Harpreet ^a   Kennedy, Andrew ^b,c,d   Coldwell, Douglas ^e   Sangro, Bruno ^f,g   Salem, Riad ^h  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Wake Radiology Oncology   (United States)

^c North Carolina State University   (United States)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g UNIVERSITY OF NAVARRA   (Spain)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

colon; hepatic; rectum; SIRT; Yttrium 90

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; YTTRIUM 90;

ANTIANGIOGENIC THERAPY; ARTIFICIAL EMBOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; RADIOEMBOLIZATION; REVIEW; SALVAGE THERAPY;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS;

EID: 84861528516     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182005747     Document Type: Review

References (51)

1. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with adVanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-379
2. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. Presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2008;26(May 20 suppl):1006s. Abs 2
3. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIRSpheres plus chemotherapy versus chemotherapy alone for treating patients with liver metastases from primary large bowel cancer Ann Oncol. 2001;12:1711-1720
4. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus Fluorouracil/Leucovorin chemotherapy versus Fluorouracil/Leucovorin chemotherapy alone in adVanced colorectal cancer. J Surg Oncol. 2004;88:78-85
5. Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25:1099-1106
6. Lim L, Gibbs P, Yip D, et al. A prospective evaluation of treatment with selective internal radiation therapy (SIR-Spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer. 2005;5:132
7. Van Hazel GA, Pavlakis N, Goldstein D, et al. Treatment of 5- fluourouracil-refractory patients with liver metastases from colorectal cancer using yttrium 90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol. 2009;27: 4089-4095
8. Cosimelli M, Mancini R, Carpanese L, et al. Clinical safety and efficacy of 90yttrium resin microspheres alone in unresectable, heavily pre-treated colorectal liver metastases: results of a phase II trial. Presented as a poster at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2008; 26(May 20 suppl):197s. Abs 4078
9. Twelves C, Xeloda Colorectal Cancer Group. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer. 2002;38(suppl 2):15-20
10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342
11. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol. 2007;25:1539-1544
12. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-2319
13. Wilke H, Glynne-Jone R, Thaler J, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study. J Clin Oncol. 2008;26:5335-5343
14. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-1664
15. Gubanski M, Naucler G, Almerud A, et al. Capecitabine as third line therapy in patients with adVanced colorectal cancer. Acta Oncologica. 2005;44:236-239
16. Van den Eynde M, Hendlisz A, Peeters M, et al. Prospective randomized study comparing intra-arterial injection of yttrium-90 resin microspheres with protracted IV 5 FU continuous infusion versus IV 5 FU continuous infusion alone for patients with liverlimited metastatic colorectal cancer refractory to standard chemotherapy. Presented as a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol 2009;27(suppl 7s):191s. Abs 4096.
17. Van Hazel G, Turner D, Gebski V. Impact of 90Y resin microspheres on health-related quality of life (HRQoL) in patients with colorectal cancer (CRC) liver metastases receiving first-line chemotherapy. Presented as a poster at the American Society of Clinical Oncology (ASCO). Gastrointestinal Cancers Symposium 2009:269. Abs 419
18. Tan TH, Kosmider S, Yip D, et al. Clinical experience of selective internal radiation therapy in combination with systemic chemotherapy as first-line therapy in patients with unresectable hepatic metastases from colorectal cancer. Presented as an abstract at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2008;26(May 20 suppl):Abs 15080
19. Tournigand C, CerVantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in adVanced colorectal cancer-a GERCOR study. J Clin Oncol. 2006;24:394-400
20. Goldberg R, Sargent D, Morton R, et al. A randomized controlled trial of fluorouracil plus leucovorin leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30
21. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in adVanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947
22. Kalofonos H, AraVantinos G, Kosmidis P, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as firstline treatment in adVanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol. 2005;16:869-877
23. Hochster HS, Welles L, Hart L, et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 and 2 studies. Presented as an abstract at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2005;23(16 suppl):2495. Abs 3515
24. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-2019
25. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer New Engl J Med. 2009;360:1408-1417
26. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin and oxaliplatin with and without cetuximab in the firstline treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 27:663-671
27. De Cerqueira Mathias C, Perazzo F, Simon S, et al. Front cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study. Presented as a poster at ECCO 14 - the European Cancer Congress. Eur J Cancer Suppl 2007;5:252-253. Abs P3055
28. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345
29. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer Cancer. 2007;110:980-988
30. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, singlearm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008;19:92-98
31. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009;115:1849-1858
32. Seidensticker M, Rühl R, Kraus P, et al. Radioembolization with yttrium-90 resin microspheres as a salvage treatment for refractory liver-dominant colorectal metastases: a matched-pair analysis Presented as a poster at ECCO 15/34th ESMO. Eur J Cancer Suppl. 2009;7:343. Abs. 6071
33. Jakobs TF, Hoffmann RT, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19:1187-1195
34. Kennedy A, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412-425
35. Kennedy A. 90Y-microsphere brachytherapy in unresectable colorectal liver metastases. Am J Hemat Oncol Review. 2006; 5:1-5
36. Kennedy A, Kreuk P, Dezarn W, et al. Analysis of anti-VEGF and anti-EGFR therapy on 90Y microsphere radiotherapy for colorectal liver metastases: a prospective study. Presented as a poster at the American Society of Clinical Oncology (ASCO). Gastrointestinal Cancers Symposium. 2009:190. Abs 260
37. Kennedy A, Kreuk P, Jakobs T, et al. Effects of anti-angiogenic therapy and chemotherapy on 90Y-microsphere treatment of colorectal liver metastases. Presented at the 20th International Congress on Anti Cancer Treatment. Proceedings of the International Congress on Anti-Cancer Treatment. 2009:247-248. Abs IC/AB159
38. Sharma RA, Wasan HS, Love SB, et al. FOXFIRE: a phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases in patients with colorectal cancer. Clin Oncol (R Coll Radiol). 2008;20:261-263
39. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00766220
40. Seymour MT, Maughan TS, Ledermann JA, et al.; National Cancer Research Institute Colorectal Clinical Studies Group Different strategies of sequential and combination chemotherapy for patients with poor prognosis adVanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370: 143-152
41. Hurwitz H, Fehrenbacher L, Hainsworth J, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508
42. Folprecht G, Grothey A, Alberts S, et al. NeoadjuVant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16: 1311-1319
43. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in adVanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370:135-142
44. Hoffmann RT, Jakobs TF, Kubisch C, et al. Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease-is it feasible? Eur J Radiol. 2009. ePub doi:10.1016/j.ejrad.2009. 02.001
45. Van Cutsem E, Blijham G. Irinotecan versus infusional 5- fluorouracil: a phase III study in metastatic colorectal cancer following failure on first line 5-fluorouracil. V302 Study Group Semin Oncol. 1999;26:13-20
46. Schoemaker N, Kuppens I, Moiseyenko V, et al. A Randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer Brit J Cancer. 2004;91:1434-1441
47. Van Cutsem E, Dirix L, Van Laethem J, et al. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Brit J Cancer. 2005;92:1055-1062
48. Folprecht G, Gruenberger T, Bechstein WO, et al. ''Tumour response and secondary resectability of colorectal liver metastases following neoadjuVant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.'' Lancet Oncol. 2010;11:38-47
49. Van den Eynde M, Flamen P, El Nakadi I, et al. Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med. 2008;33:697-699
50. Siddiqi NH, Devlin PM. Radiation lobectomy-A minimally invasive treatment model for liver cancer: case report. J Vasc Interv Radiol. 2009;20:664-669
51. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium (REBOC) Int J Radiat Oncol Biol Phys. 2007;68:13-23